Why Boston Scientific (BSX) shares are plunging today

Shares of Boston Scientific (NYSE:BSX), a prominent medical device manufacturer, experienced an 8% decline during the morning trading session following the release of its financial results for the third quarter of 2026. The company reported a modest net sales growth of 1.5% and discussed its ongoing efforts to recover from a recent cybersecurity incident.

In a press release, Boston Scientific announced that its net sales increased by 1.5% on both a reported and operational basis, reaching $5.138 billion. The company reported a GAAP net income of $582 million, translating to earnings of $0.40 per share. Adjusted earnings per share were $0.73, slightly exceeding analysts' expectations of $0.72, as per S&P estimates.

Chairman and CEO Mike Mahoney emphasized the company's commitment to restoring normal operations in the wake of the cybersecurity breach. The lackluster sales growth, combined with the ongoing impact of the cybersecurity incident, negatively influenced investor perceptions.

Market reactions to news can often be exaggerated, and sharp declines in stock prices may present opportunities for investors to acquire high-quality stocks at lower prices. Given the current situation, some investors may wonder if now is the right time to invest in Boston Scientific. A detailed analysis report is available for those interested.

Boston Scientific's stock has shown relative stability, with only nine instances of price fluctuations exceeding 5% over the past year. Today's drop suggests that the market views this news as significant, although it may not alter the overall perception of the company's long-term prospects.

One of the most notable stock movements occurred nine months ago when Boston Scientific shares fell by 13.9% after the company announced its fourth-quarter 2025 results. Although the results exceeded Wall Street's expectations, the mixed guidance for the future raised concerns among investors. The company reported quarterly revenues of $5.29 billion and adjusted earnings per share of $0.80, surpassing analysts' predictions of $5.27 billion in revenue and $0.78 in earnings. However, the cautious outlook overshadowed the positive quarterly performance, leading to a significant sell-off.

Year-to-date, Boston Scientific's stock has plummeted by 55.7%. Currently, shares are priced at $41.92, which is 60.1% below their 52-week high of $104.98, reached in November 2025. For investors who purchased $1,000 worth of Boston Scientific's stock five years ago, the value of that investment would now stand at approximately $969.47.